References
- Maslov M, Foianini S, Lovich M. Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease. Expert Opin Drug Deliv. 2017;1–13.
- Fargnoli AS, Katz MG, Williams RD, et al. A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression. J Cardiovasc Transl Res. 2014;7(8):756–767.
- Nishizaki K, Mazda O, Dohi Y, et al. In vivo gene gun-mediated transduction into rat heart with Epstein-Barr virus-based episomal vectors. Ann Thorac Surg. 2000;70(4):1332–1337.
- Grossman PM, Han Z, Palasis M, et al. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv. 2002;55(3):392–397.
- Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 2000;13(4):238–287.
- Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010;16(9):1035–1041.
- Fargnoli AS, Mu A, Katz MG, et al. Anti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection. J Transl Med. 2014;12:171.
- Von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–423.
- Katz MG, Fargnoli AS, Bridges CR. Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability. Hum Gene Ther. 2013;24(4):375–392.